文章：

乳腺癌患者新辅助化疗前后健康相关生活质量与疾病接受度研究

Health-Related Quality of Life and Disease Acceptance Among Women with Breast Cancer Pre- and Post-Neoadjuvant Chemotherapy

原文发布日期：2 February 2025

DOI: 10.3390/cancers17030497

类型: Article

开放获取: 是

英文摘要：

Background/Objective:The study aimed to evaluate disease acceptance and quality of life in women with breast cancer before and after receiving neoadjuvant chemotherapy.Methods:The study included 211 women diagnosed with breast cancer who underwent neoadjuvant treatment. The following measures were utilized: the EORTC QLQ-C30 and QLQ-BR23 modules for quality of life assessment, the Acceptance of Illness Scale (AIS) questionnaire for evaluating disease acceptance, and a proprietary questionnaire. Assessments were conducted one week before the first chemotherapy session and three weeks after completing the chemotherapy. Statistical analysis was performed using STATISTICA v. 13.Results:The respondents exhibited an average acceptance of their disease, both before (28.2 pts) and after chemotherapy (25.5 pts). A decline in disease acceptance was observed in nearly 59.2% of the patients following chemotherapy. Higher levels of disease acceptance were associated with a better quality of life. The quality of life for the studied women decreased after neoadjuvant chemotherapy, particularly in the following areas: physical functioning (p= 0.0000), social functioning (p= 0.0000), body image assessment (p= 0.0000), sexual satisfaction (p= 0.0000), nausea and vomiting (p= 0.0000), fatigue (p= 0.0000), loss of appetite (p= 0.0000), insomnia (p= 0.0000), pain (p= 0.0000), hair loss (p= 0.0000), and side effects of systemic treatment (p= 0.0000).Conclusions:Post-neoadjuvant chemotherapy, a decline in disease acceptance and quality of life was observed among women with breast cancer in comparison with their pre-treatment status. Higher levels of disease acceptance were associated with a better quality of life. These findings may facilitate the creation of a more tailored care approach for women during and after chemotherapy.

摘要翻译： 

背景/目的：本研究旨在评估乳腺癌女性患者在接受新辅助化疗前后对疾病的接受程度及其生活质量变化。 方法：研究纳入211例确诊为乳腺癌并接受新辅助治疗的患者。采用以下评估工具：欧洲癌症研究与治疗组织生活质量核心量表（EORTC QLQ-C30）及乳腺癌特异性模块（QLQ-BR23）评估生活质量，疾病接受度量表（AIS）评估疾病接受度，并辅以自设问卷。分别在首次化疗前一周及化疗结束后三周进行评估。使用STATISTICA v.13软件进行统计分析。 结果：研究对象在化疗前（28.2分）与化疗后（25.5分）均呈现中等水平的疾病接受度。化疗后约59.2%的患者疾病接受度下降。疾病接受度越高者，其生活质量越好。新辅助化疗后患者生活质量普遍下降，尤其在以下维度表现显著：躯体功能（p=0.0000）、社会功能（p=0.0000）、体像评价（p=0.0000）、性满意度（p=0.0000）、恶心呕吐（p=0.0000）、疲乏（p=0.0000）、食欲减退（p=0.0000）、失眠（p=0.0000）、疼痛（p=0.0000）、脱发（p=0.0000）及全身治疗副作用（p=0.0000）。 结论：新辅助化疗后，乳腺癌女性患者的疾病接受度及生活质量较治疗前均有所下降。疾病接受度与生活质量呈正相关关系。这些发现有助于为化疗期间及化疗后的患者制定更具个体化的照护方案。

原文链接：

Health-Related Quality of Life and Disease Acceptance Among Women with Breast Cancer Pre- and Post-Neoadjuvant Chemotherapy